Abstract:OBJECTIVETo investigate the expression of integrin beta3 and osteopontin (OPN) in eutopic and ectopic endometrium of adenomyosis.METHODSFrom January 2007 to July 2008, the endometrium specimens were collected from 43 patients with adenomyosis undergoing hysterectomy in Peking University First Hospital. Eutopic endometrium were 11 in proliferative phase and 32 in secretory phase (18 cases in mid-secretory phase) were collected. Ectopic endometriums were also collected. In the mean time, it was chosen 41 cases with pure subserous uterine myoma or cervical intraepithelial neoplasia (CIN) II-III treated by hysterectomy as controls including 12 endometrium in proliferative phase and 29 endometrium in secretory phase (19 cases in mid-secretory phase). The expression of Integrin beta3 subunit and OPN in the endometrium were assessed by immunohistochemical staining and quantitative real-time polymerase chain reaction.RESULTS(1) Immunohistochemical staining showed that positive staining of integrin beta3 and OPN were present predominantly in eutopic and ectopic endometrial glandular epithelium. There was significant different protein expression of integrin beta3 and OPN, which were 1.6 +/- 0.8 and 1.7 +/- 0.7 in eutopic endometrium, 1.7 +/- 0.7 and 1.8 +/- 0.9 in ectopic endometrium, 2.1 +/- 0.9 and 2.0 +/- 0.9 in control endometrium (P < 0.05). The protein expression of integrin beta3 and OPN in eutopic endometrium of adenomyosis in the proliferative phase (0.8 +/- 0.4 and 0.7 +/- 0.3) were remarkably lower than those of the secretory phase (1.8 +/- 0.8 and 1.9 +/- 0.8, P < 0.01). The protein expression of integrin beta3 and OPN in the endometrium of controls in the proliferative phase (1.0 +/- 0.4 and 1.0 +/- 0.4) were significantly lower than those of the secretory phase (2.5 +/- 0.7 and 2.5 +/- 0.7) (P = 0.000). In the mid-secretory phase, the protein expression of integrin beta3 (2.0 +/- 0.9) and OPN (2.1 +/- 0.8) in eutopic endometrium of adenomyosis were significantly lower than that of control endometrium (2.7 +/- 0.5 and 2.7 +/- 0.7) (P < 0.01). (2) The mRNA expression level of integrin beta and OPN in eutopic and ectopic endometrium were assessed by quantitative real-time PCR (result was shown by median index). It was observed that integrin beta3 mRNA and OPN mRNA were significantly lower in the eutopic endometrium of adenomyosis (4.69 and 4.23), when compared with ectopic endometrium (7.96 and 14.84) and controls (13.47 and 17.40) (P < 0.05). Eutopic endometrium had higher mRNA expression of integrin beta and OPN mRNA in the secretory phase (5.54 and 11.40) than that in the proliferative phase (2.69 and 3.30) (P < 0.01). The mRNA expression level of integrin beta and OPN of control endometrium in the proliferative phase (3.12 and 4.75) were significantly lower than that in the secretory phase (19.94 and 21.00, P = 0.000). The mRNA expression of integrin beta and OPN were 10.10 and 14.34 in the mid-secretory phase, which were significantly lower than 21.50 and 24.18 in control endometrium (P < 0.05).CONCLUSIONSHigh expression of integrin beta3 and OPN in ectopic endometrium of adenomyosis may cause endometriotic lesions; abnormal expression of integrin beta3 and OPN in the endometrium of adenomyosis during the implantation window may contribute to infertility in some patients.

Immunoreactivity of Progesterone Receptor Isoform B, Nuclear Factor Kappab, and IkappaBalpha in Adenomyosis.

Immunoreactivity of Progesterone Receptor Isoform B, Nuclear Factor Κb, and IκBα in Adenomyosis

Increased endometrial expression of CC-chemokine receptor-1 in women with adenomyosis.

[Distribution of Nerve Fibers in Endometrium and Its Clinical Significance in Adenomyosis].

Innervation of Endometrium and Myometrium in Women with Painful Adenomyosis and Uterine Fibroids.

Expression of Progesterone Receptor Subtypes in Ectopic Endometrium of Adenomyosis

Immunoreactivity of CD 68 , granulocyte-macrophage colony-stimulating factors receptor and vonWillebrand factor and its association with dysmenorrhea severity and the amount of menses in adenomyosis

The expression and methylation of PR-B in adenomyosis

Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its correlation with dysmenorrhea in adenomyosis.

Increased Immunoreactivity to SLIT/ROBO1 and Its Correlation with Severity of Dysmenorrhea in Adenomyosis

Temporal and Spatial Expression of Estrogen Activity-Related Molecules in Eutopic Endometrium of Adenomyosis

Elevated Immunoreactivity Against Class I Histone Deacetylases in Adenomyosis.

Aberrant Immunoreactivity of Deoxyribonucleic Acid Methyltransferases in Adenomyosis.

Immunoreactivity of Progesterone Receptor Isoform B and Nuclear Factor Kappa-B As Biomarkers for Recurrence of Ovarian Endometriomas

Elevated Immunoreactivity to Tissue Factor and Its Association with Dysmenorrhea Severity and the Amount of Menses in Adenomyosis.

Expression and clinical significance of Akt and NF-κB in adenomyosis

Cytokine Profiling in the Eutopic Endometrium of Adenomyosis During the Implantation Window after Ovarian Stimulation

Expression of Endometrial Receptivity Markers throughout the Menstrual Cycle in Women with and without Uterine Adenomyosis

Study of Cell Apoptosis and Bcl-2 Expressions in the Ectopic Nidus of Adenomyosis

[Expression of Integrin Beta3 and Osteopontin in Endometrium of Patients with Adenomyosis].

Mifepristone Inhibited the Expression of B7-H2, B7-H3, B7-H4 and PD-L2 in Adenomyosis